Advertisement

Topics

Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo

13:46 EDT 12 Oct 2018 | SCRIP

Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several...

      

Related Stories

 

Original Article: Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo

NEXT ARTICLE

More From BioPortfolio on "Bristol’s Checkmate-331 Failure Not Likely To Endanger SCLC Labeling For Opdivo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...